Precision biopharmaceutical developer AbelZeta Pharma, Inc. announced on Tuesday, November 10, 2026, that the United States Food and Drug Administration granted dual regulatory milestones for its investigational cellular therapy. The agency awarded both Regenerative Medicine Advanced Therapy and Fast Track designations to prizlon-cel, formerly designated C-CAR039. The cellular immunotherapy candidate targets relapsed or refractory large B-cell lymphoma. Engineered to bind simultaneously to CD19 and CD20 antigens, the bi-specific CAR-T circumvents single-antigen tumor escape mechanisms that frequently drive relapse following conventional cellular treatments.
Prizlon-cel shows 91.5 percent response in 48 patients
Clinical efficacy profiles generated across early-phase patient cohorts demonstrated durable disease control in challenging oncologic environments. Clinical responses proved robust. Across 48 evaluated trial participants, prizlon-cel elicited an overall response rate of 91.5 percent alongside a complete response rate of 85.1 percent. Long-term longitudinal follow-up indicated a two-year progression-free survival rate of 62.6 percent. Dual-targeting receptor architecture prevented malignant clones from evading immune surveillance through target loss.
Addressing oncology researchers during an investor symposium on Tuesday, the Chief Executive Officer of AbelZeta outlined the development pathway. The chief executive stated: "Securing dual FDA RMAT and Fast Track designations represents a transformative milestone for the global clinical development of prizlon-cel. Our priority program focuses on patients whose disease progressed after prior CAR T-cell therapies, offering meaningful clinical responses to a population with urgent unmet needs."
The regulatory classifications confer valuable operational advantages throughout prospective registration pathways with federal health officials. Agency collaboration deepens. The program secures intensive FDA procedural guidance, senior review staff engagement, and eligibility for rolling review of Biologics License Application modules. AbelZeta confirmed active operational preparations to commence a prospective phase 2 clinical registration program across premier oncology research centers in the United States.
Experts endorse bispecific CAR-T and 2027 phase 2 enrollment
Academic hematologists and cellular therapy specialists commended the clinical advances. In an expert editorial published on Tuesday, a clinical lymphoma research director at a leading cancer center noted: "Target antigen loss remains a primary vulnerability undermining the durability of early-generation CD19 autologous CAR-T products. Demonstrating an 85 percent complete response rate with two-year durability validates bispecific targeting. Expedited regulatory pathways provide crucial momentum toward addressing post-CAR-T therapeutic failures."
AbelZeta expects to initiate patient enrollment across United States phase 2 trial sites during the first half of 2027.
Alongside securing expedited FDA regulatory designations, AbelZeta confirmed the completion of commercial-scale manufacturing validation protocols for prizlon-cel. Commercial scale-up advanced.
Closed-system bioreactors support prizlon-cel manufacturing scale-up
The company's commercial bioprocessing facilities feature automated, closed-system bioreactor suites that maintain exceptional cellular transduction efficiency and product viability. Advanced cryopreservation logistics networks ensure that patient-specific autologous cellular therapies transfer safely to clinical trial centers under continuous temperature monitoring. Therapeutic supply chains remained robust.
Addressing delegates during a global cellular therapy manufacturing congress on Tuesday, the Quality Control Chair of the International Society for Cell & Gene Therapy noted: "Manufacturing consistency across bi-specific CAR-T constructs directly influences patient clinical outcomes. Engineering rigorous closed-system production standards provides a reliable foundation for prospective multicenter commercialization." Oncology teams welcomed the manufacturing milestone.
In addition, clinical oncology directors and cellular immunotherapy researchers emphasized that bi-specific targeting constructs demonstrate significant therapeutic potential for patients who have exhausted all standard salvage chemotherapy regimens. By preventing single-antigen escape mechanisms, dual-targeting therapies provide a promising new treatment avenue for aggressive hematologic malignancies.
Stakeholders anticipate 2027 programmatic updates and partnerships
In addition, international regulatory compliance fellows and economic research directors emphasized that structured policy implementation reinforces operational stability across institutional environments. Industry stakeholders look forward to forthcoming programmatic updates as organizations advance their strategic priorities throughout 2027. Collaborative partnerships continue to foster sustainable growth across global commercial and public institutions.
